Company Profile - JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED สำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ Printed on 09 August 2024 20:12 Company Profile JSP

. OCMSET/6201/006 January 30, 2019 Re: Management Plan after Discontinuation of Business of Manufacturing Accessories and Faucet Products, the Disposition of Assets Relating to Such Business. Attn

. OCMSET/6201/006 January 30, 2019 Re: The Disposition of Assets Relating to the Business of Manufacturing Accessories and Faucet Products which the Board of Directors’ Meeting No. 9/2018 Has Approved to

investment disposal that had a significant impact on the financial statements of the IPO applicant, and the payment of a large sum of consultant fee for services the applicant might never receive; such actions

-150 grew by 1.4%. Chalarm continued its strong momentum after the newly launched Black Galingale variant in August 2018 where sales grew +17.2% YoY. Som In-Sum growth remained strong (+37.8% YoY

contraction led to the decline in manufacturing production and private investment. Together with uncertainties in the trade relationship, weaker global economy, and the Thai Baht’s depreciation. On the domestic

THB 342 million), driven by growth in both beverage and personal care businesses. Beverage segment grew from all major categories, including flagship brand M-150, herbal-variant Som In-Sum and Chalarm

the interest income to be received throughout the period of 2.5 years until the full sum of investment capital sale is received between 2020 to the mid of 2022. 2. For the year 2019, the expenses of

ที่ กบร No. Kor Bor Ror. 032/2017 November 9, 2017 President The Stock Exchange of Thailand Re : Increase of the investment proportion in the ordinary shares of Pattaya Manufacturing Co., Ltd. Dear

holding shares in the Greater China Project, the Group nevertheless benefits from manufacturing and exporting our products to our trade partner in the People’s Republic of China for marketing for the